Biodel reported plans to build and operate a fill and finish manufacturing facility for its Phase III injectable insulin product, VIAject™.
Biodel anticipates that the site will cost under $15 million. The plant, to be located on the campus of Biodel’s headquarters in Danbury, CT, will be available for commercial production in 2009, according to the company.
The firm expects that the dedicated production plant will improve margins, provide superior quality control, and better inventory control.
VIAject is Biodel’s lead candidate. It is being developed as a rapid-acting form of injectable human insulin for meal-time use by patients with type 1 or type 2 diabetes.